G-CSF and its receptor in myeloid malignancy

Renée Beekman1 and Ivo P. Touw1

1Department of Hematology, Erasmus MC, Rotterdam, The Netherlands

Granulocyte colony-stimulating factor (G-CSF) has been used in the clinic for more than 2 decades to treat congenital and acquired neutropenias and to reduce febrile neutropenia before or during courses of intensive cytoreductive therapy. In addition, healthy stem cell donors receive short-term treatment with G-CSF for mobilization of hematopoietic stem cells. G-CSF has also been applied in priming strategies designed to enhance the sensitivity of leukemia stem cells to cyttotoxic agents, in protocols aimed to induce their differentiation and accompanying growth arrest and cell death, and in severe aplastic anemia and myelodysplastic syndrome (MDS) to alleviate anemia. The potential adverse effects of G-CSF administration, particularly the risk of malignant transformation, have fueled ongoing debates, some of which can only be settled in follow-up studies extending over several decades. This specifically applies to children with severe congenital neutropenia who receive lifelong treatment with G-CSF and in which the high susceptibility to develop MDS and acute myeloid leukemia (AML) has now become a major clinical concern. Here, we will highlight some of the controversies and challenges regarding the clinical application of G-CSF and discuss a possible role of G-CSF in malignant transformation, particularly in patients with neutropenia harboring mutations in the gene encoding the G-CSF receptor. (BLOOD. 2010;115(25):5131-5136)

G-CSF and its receptor

The growth factor granulocyte colony-stimulating factor (G-CSF), now referred to as CSF3, is the major regulator of neutrophil production under basal conditions of hematopoiesis, as is evident from the fact that CSF3 or CSF3 receptor–deficient mice are severely neutropenic.1,2 CSF3 is also essential for “emergency” granulopoiesis in response to bacterial infections and enhances multiple neutrophil functions.3 CSF3 exerts its role by inducing proliferation and survival of myeloid progenitor cells, followed by a cell-cycle arrest and neutrophilic differentiation.4 The receptor for CSF3 (CSF3R) belongs to the cytokine receptor type I superfamily, which engages the canonical Janus kinase (Jak)/signal transducer and activator of transcription (STAT), Ras/Raf/MAP kinase, and PKB/Akt pathways. When CSF3R mutants were expressed in differentiation competent factor–dependent myeloid cell lines, the distal cytoplasmic region of the CSF3R of approximately 100 amino acids was crucial for CSF3-induced neutrophilic differentiation of these cells.5 Although originally being considered as “differentiation domain,” later studies demonstrated that this C-terminal region exerts a negative role in STAT5 activation and proliferation signaling in vivo.6,7 Negative regulators of CSF3 signaling linked to the distal C-terminus of CSF3R include the protein tyrosine phosphatases SHP-1 and the suppressor of cytokine signaling (SOCS) protein SOCS3. The SOCS protein family is characterized by a so-called SOCS box, a domain involved in the recruitment of ubiquitin (E3) ligase activity. The negative action of SOCS3 and more specifically of its SOCS box on CSF3 signaling has been demonstrated in conditional knockout models.8,9 A mechanism for receptor down-regulation has been proposed in which SOCS3 drives ubiquitination of a conserved juxtamembrane lysine residue that is important for lysosomal routing of the receptor, is important for neutrophil production, particularly during episodes of emergency granulopoiesis.4,10

CSF3 in the treatment of AML

CSF3 as a differentiation-inducing agent

Soon after Bradley and Metcalf11 and Pluznik and Sachs12 discovered in the mid-1960s that bone marrow progenitor cells form colonies of differentiated myeloid cells under the influence of external growth factors, it became clear that these crude growth factor preparations also stimulated the proliferation and in part differentiation of leukemic progenitors in acute myeloid leukemia (AML).13 Once this was realized, ideas about the potential therapeutic significance of these findings rapidly evolved, which became testable in the mid-1980s when recombinant technology allowed the large-scale production and purification of hematopoietic growth factors, including CSF3.14,15 The availability of clinical-grade CSF3 and GM-CSF yielded expectations for patients with severe forms of chronic neutropenia, which have proved to be realistic from the outset. Concerning the application of CSF3 in the treatment of myeloid leukemia, one line of thinking was that AML blasts would differentiate upon CSF3 exposure and thereby undergo growth arrest and cell death.16,17 These studies provided important insights in the biology of myeloid leukemia and, for example, revealed the hierarchical nature of leukemic cell populations, consisting of leukemic stem cells, progenitors with colony-forming potential in vitro (AML-CFU), and partly differentiated nonproliferative end cells.13 Since then, CSF3 has occasionally been administered to selected patients with AML with the objective to induce differentiation of the leukemic cells with variable results; whether the observed therapeutic effects could be ascribed to
of patients with AML have a 2- to 5-fold increase in the annual incidence of leukemia, which most likely explains this discrepancy.30

Another context in which a possible leukemogenic effect of CSF3 has been extensively investigated is in adjuvant breast cancer therapy. A retrospective study addressed the occurrence of AML/MDS in 6 adjuvant breast cancer trials and showed increased rate of AML/MDS in patients treated with intensified doses of cyclophosphamide requiring CSF3 support.31 A different study reported a doubling in the risk of AML/MDS in a population of women aged 65 years or older treated with adjuvant chemotherapy and growth factor support for stages I to III breast cancer.32 Although the absolute risk of secondary leukemia was low in both studies, it was stated that the application of myeloid growth factors and possible leukemia risk should be factored into clinical decisions. However, the benefits of adjuvant chemotherapy in these patients outweigh the risk of secondary MDS or AML and, given all of the unknown factors, it remains uncertain whether the weak associations found have a causal relationship to growth factor treatment.33 Interestingly, a recent study in an as-yet small series of patients suggests that the mutational status of BRCA1 and BRCA2 genes may contribute to leukemia risk in patients with breast cancer, raising the possibility that a relation between CSF3 administration and secondary MDS/AML may specifically apply to these genetically defined subgroups.34 Although a follow-up of 2000 stem cell donors for at least 10 years might be needed to detect a statistically significant increase in malignant transformation,29 the leukemia incidence associated with CSF3 administration is thus far negligible in stem cell donors and low but not yet conclusively determined in different genetic subtypes in patients with breast cancer.

CSF3 treatment and malignant transformation in conditions with increased leukemia risk

CSF3, as a single growth factor or in combination with erythropoietin (EPO), has been used in MDS and severe aplastic anemia (SAA) and MDS, but is not generally applied in the treatment of these conditions. In MDS, CSF3 was administered to investigate whether CSF3 would synergize with EPO to alleviate anemia and to reduce transfusion need.35 A collaborative study that included patients from all risk categories suggested that leukemia risk in patients with MDS treated with a combination of CSF3 and EPO was not different from patients not receiving growth factor treatment.36 However, a complicating factor in this retrospective study is that the EPO plus CSF3–treated groups were compared with untreated historic controls from a distinct cohort.36 In a retrospective survey among 840 patients with SAA registered by the European Group for Blood & Marrow Transplantation (EBMT) who received immunosuppressive therapy (IST) with or without CSF3, a small but significant increase in hazard (1.9) of AML/MDS was reported in the CSF3-treated group.37 In contrast, in a meta-analysis of 6 randomized control trials involving a total of 414 patients, no statistically different risk of progression to MDS/AML between growth factor–treated and control groups was noted.38 A similar conclusion was reached in an earlier study based on 144 patients.39 Strikingly, in a Japanese study, CSF3 treatment appeared to be more strongly associated with increased leukemia risk, particularly in patients refractory to IST.40 Why the leukemia incidence in this study differed from the European studies37–39 is unclear, but may relate to a more frequent occurrence of chromosome 7 abnormalities (monosomy 7, 7q-) in the Japanese patient group.40 Supporting this idea, Sloand and colleagues showed that CSF3 preferentially stimulates the clonal expansion of MDS and

CSF3 as a chemosensitizer

The use of myeloid growth factors (CSF3, GM-CSF) to activate chemoresistant dormant LSCs into chemosensitive cycling cells has been tested in multiple prospective randomized trials with variable outcome, possibly because of differences in patient groups and study design.20 For instance, in one study, beneficial effects on overall and disease-free survival of standard-risk patients with AML was demonstrated when CSF3 was administered during induction therapy,21 whereas others did not observe favorable responses in a similar study involving elderly patients with AML.22 More recently, the theme of chemosensitization of LSCs by growth factor priming has been revisited from another viewpoint (ie, based on the ability of CSF3 and the CXCR4 antagonist AMD3100 [plerixafor] to push LSCs out of their bone marrow niches that promote self-renewal and may be protective against damage by genotoxic compounds). Again, results may be variable and dependent on the subtype of AML, as is illustrated by 2 recent studies in mouse models, one representing acute promyelocytic leukemia (APL), the other representing AML with high MN1 expression. In the APL model, it was shown that AMD3100 induces the mobilization of leukemic cells from their bone marrow niches into the circulation, thereby increasing their sensitivity to Ara-C or daunorubicin.23 In contrast, no chemosensitizing effects were seen in the AML/MN1 model.24 Despite the similarities in mobilizing activities of CSF3 and AMD3100, recent studies have shown that CSF3 and AMD3100 synergize in the mobilization of normal stem cells, suggesting that their activities are not entirely overlapping.25 These observations suggest that combinations of CSF3 and AMD3100 or other agents affecting cell migration and adhesion might be of therapeutic benefit.26

CSF3 and malignant transformation

Leukemia risk in persons without hematologic disorders

The concern that administration of hematopoietic growth factors might accelerate or even cause leukemia has recently received major attention in the context of CSF3 treatment of healthy persons to mobilize hematopoietic stem cells (HSCs) into the periphery. The adverse effects of CSF3 administration to peripheral stem cell donors have been evaluated in 2 independent studies involving more than 5000 patients with a follow-up of 4 to 5 years.27,28 Both studies reported no statistically significant differences in the incidence of malignancy relative to persons not exposed to growth factor treatment. On the other hand, in a study from the Research on Adverse Drug Events and Reports (RADAR) project,29 AML was reported in 2 of 200 HLA-identical siblings donors for patients with AML, which significantly exceeds the incidence reported in the other studies. However, irrespective of exposure to CSF3, siblings

differentiation induction remained uncertain.18 Currently, the interest in further clinical development of this concept appears to have diminished, arguably because differentiation of the leukemia "bulk" without affecting the leukemia stem cells (LSCs) may not lead to durable therapeutic benefits. Nonetheless, the successful implementation of all-trans retinoic acid therapy in the treatment of acute promyelocytic leukemia, serving as the key paradigm that differentiation-inducing agents combined with chemotherapeutic regimens can result in long-lasting remissions,19 leaves the concept of differentiation induction by combinations of agents (including CSF3) open for future application in AML.

CSF3 as a chemosensitizer

The use of myeloid growth factors (CSF3, GM-CSF) to activate chemoresistant dormant LSCs into chemosensitive cycling cells has been tested in multiple prospective randomized trials with variable outcome, possibly because of differences in patient groups and study design.20 For instance, in one study, beneficial effects on overall and disease-free survival of standard-risk patients with AML was demonstrated when CSF3 was administered during induction therapy,21 whereas others did not observe favorable responses in a similar study involving elderly patients with AML.22 More recently, the theme of chemosensitization of LSCs by growth factor priming has been revisited from another viewpoint (ie, based on the ability of CSF3 and the CXCR4 antagonist AMD3100 [plerixafor] to push LSCs out of their bone marrow niches that promote self-renewal and may be protective against damage by genotoxic compounds). Again, results may be variable and dependent on the subtype of AML, as is illustrated by 2 recent studies in mouse models, one representing acute promyelocytic leukemia (APL), the other representing AML with high MN1 expression. In the APL model, it was shown that AMD3100 induces the mobilization of leukemic cells from their bone marrow niches into the circulation, thereby increasing their sensitivity to Ara-C or daunorubicin.23 In contrast, no chemosensitizing effects were seen in the AML/MN1 model.24 Despite the similarities in mobilizing activities of CSF3 and AMD3100, recent studies have shown that CSF3 and AMD3100 synergize in the mobilization of normal stem cells, suggesting that their activities are not entirely overlapping.25 These observations suggest that combinations of CSF3 and AMD3100 or other agents affecting cell migration and adhesion might be of therapeutic benefit.26

CSF3 and malignant transformation

Leukemia risk in persons without hematologic disorders

The concern that administration of hematopoietic growth factors might accelerate or even cause leukemia has recently received major attention in the context of CSF3 treatment of healthy persons to mobilize hematopoietic stem cells (HSCs) into the periphery. The adverse effects of CSF3 administration to peripheral stem cell donors have been evaluated in 2 independent studies involving more than 5000 patients with a follow-up of 4 to 5 years.27,28 Both studies reported no statistically significant differences in the incidence of malignancy relative to persons not exposed to growth factor treatment. On the other hand, in a study from the Research on Adverse Drug Events and Reports (RADAR) project,29 AML was reported in 2 of 200 HLA-identical siblings donors for patients with AML, which significantly exceeds the incidence reported in the other studies. However, irrespective of exposure to CSF3, siblings
SAA clones with monosomy 7, which was linked to an increased expression of a CSF3R isoform that lacks a major part of the C-terminal cytoplasmic domain as a result of alternative splicing. On the other hand, IST-unresponsive patients with SAA not receiving CSF3 therapy may also develop monosomy 7. In summary, although the increase of leukemia risk upon CSF3 treatment of patients with MDS and patients with SAA appears to be low, a causal relationship cannot be entirely excluded. Given the limited use of CSF3 in these settings, data from prospective trials further addressing this issue will unlikely become available in the near future.

SCN

CSF3 therapy alleviates severe neutropenia and related clinical symptoms in more than 90% of patients with severe congenital neutropenia (SCN) and is the preferred choice of treatment of SCN. In the pre–growth factor era, with early mortality due to opportunistic infections being the dominant complication, progression of SCN to acute leukemia was sporadically reported. Since 1994, the Severe Chronic Neutropenia International Registry (SCNIR) has monitored patients with different forms of neutropenia, including SCN, cyclic neutropenia, and idiopathic neutropenia. In 2000, the first comprehensive evaluation of the incidence of MDS/AML in patients with SCN from the SCNIR was reported. Among 352 patients with SCN monitored for an average of 6 years (range, 0.1-11 years) on CSF3 treatment, 31 developed MDS/AML, with a cumulative risk of 13% after 8 years of CSF3 treatment. There was no apparent relationship to duration or dose of CSF3 treatment and progression to MDS/AML. A follow-up study published in 2006 involving 374 patients with SCN showed that the hazard of MDS/AML increased over time, from 2.9% per year after 6 years to 8.0% per year after 12 years on CSF3. After 10 years, the cumulative incidence for MDS/AML was 21%. This study also specifically addressed the incidence of leukemia in patients with SCN relative to CSF3 responsiveness. Patients requiring more than the median dosage of CSF3 (8 μg/kg/d) and nonetheless did not reach median absolute neutrophil counts after 6 to 18 months had a significantly increased MDS/AML incidence (40%) after 12 years compared with patients responding to lower CSF3 doses (11%). A possible explanation for these associations is that the HSC compartment in patients with SCN who respond poorly to CSF3 is more damaged and therefore less susceptible to growth factors. This supports the notion that secondary leukemia in SCN arises because chronic genotoxic stress in the HSC compartment leads to the acquisition of oncogenic mutations, with CSF3 possibly playing a role in the clonal expansion of (pre-)leukemic cells. However, whether CSF3 therapy had contributed to MDS/AML development could not be determined in this study. Of note, patients with cyclic or idiopathic neutropenia and patients with neutropenia with an underlying metabolic disorder receiving CSF3 treatment regimens comparable to patients with SCN treatment do not show an increased propensity to develop MDS or AML. Leukemic progression of neutropenia is thus mainly confined to patients diagnosed with SCN.

CSF3R mutations and malignant transformation in SCN

Direct evidence for a possible role of CSF3 in propagating leukemic expansion comes from patients with SCN/AML in which remission of leukemia occurred after termination of CSF3 treatment. However, such patients are exceptional, and in general abrogation of CSF3 treatment has little or no effect on the leukemic burden in patients with SCN/AML. The discovery that patients may harbor nonsense mutations in the CSF3 gene, resulting in the expression of truncated CSF3R proteins lacking approximately 100 amino acids from their C-terminal cytoplasmic domains, provided a molecular indication for abnormal CSF3 signaling in SCN. Functional studies revealed that these truncated CSF3R proteins were hampered in their ability to transduce signals required for neutrophil differentiation in murine cell line models, a characteristic associated with a possible role of CSF3R dysfunction in leukemic progression of the disease. Importantly, a later study showed that the CSF3R mutations are usually not constitutive but are acquired in hematopoietic stem or progenitor cells during the course of CSF3 treatment. Another major finding of this study was that the time between the first detection of CSF3R mutations and the diagnosis of MDS/AML varied greatly. For instance, in 1 patient, a clone with an acquired CSF3R mutation appeared just 3 months before AML became overt, whereas in other patients, CSF3R mutant clones were already detected 4 years before the acquisition of monosomy 7 and disease conversion to MDS/AML. In addition, it became clear that patients may harbor multiple distinct acquired CSF3R mutations, suggestive of expansion of multiple affected clones.

The 2 major genetically defined subgroups of SCN prone to develop MDS/AML are patients with mutations in ELA2 and patients with mutations in the HAX1 gene. More recently, 2 patients with X-linked neutropenia with mutations in the WAS gene were reported in which the disease evolved to MDS/AML. In these 3 subtypes of SCN, leukemic progression is associated with the acquisition of CSF3R mutations, and until now no differences in latencies or molecular and cytologic features of the arising leukemias have been reported. In an analysis involving 145 patients with SCN, mutations were found in approximately one-third of the patients in the neutropenic phase of the disease. Of 23 patients showing signs of malignant transformation, 18 (78%) harbored CSF3R mutations, confirming that these mutations are strongly linked to leukemic predisposition. Notably, these mutations have also been detected in lymphoid cells and thus may be acquired in multipotent progenitors. In contrast to SCN, acquisition of CSF3R mutations has not been observed in patients with cyclic or idiopathic neutropenia receiving CSF3 therapy. These findings show that long-term CSF3 treatment in patients with neutropenia other than SCN is not leukemogenic and further accentuate the correlation between leukemic progression of SCN and the acquisition of CSF3R mutations. However, despite all these suggestive correlations, the issue whether these mutations are truly “drivers” or just “passengers” in the leukemic process cannot be settled with certainty. For instance, a critical piece of information that is still missing is whether CSF3R mutations, once detected in the neutropenic phase, are invariably present in the MDS/AML cells and not “lost” during leukemic progression, as was recently demonstrated for JAKV617F mutations in myeloproliferative disorders. So far, patients harboring clones with CSF3R mutations that progress to MDS/SCN without mutations have not been reported, but a systematic analysis is warranted to address this issue.

Molecular mechanisms responsible for leukemic progression of SCN

The critical genetic pathway(s) underlying the leukemic progression of SCN are still largely unknown. Cytogenetic abnormalities that are most frequently found in SCN/AML are chromosome 7 abnormalities (monosomy 7, 7q−) and trisomy 21. Mutations in Ras have also been detected in SCN/AML, but their frequency is
still controversial. By performing mutational profiling of 14 genes previously implicated in leukemogenesis, Link and colleagues found that mutations of tyrosine kinase genes FLT3, KIT, and JAK2 were not detected in SCN/AML, and neither were other abnormalities (eg, mutations in NPM1, CEBPA, and TP53) that are common in de novo AML. As expected, mutations of CSF3R were the only regular abnormalities found in SCN/AML, again supporting the hypothesis that the mutant CSF3R may provide an “activated tyrosine kinase signal” important for leukemogenesis. Aberrant signaling from the truncated CSF3R is to a major extent driven by defective ligand-induced receptor internalization because of the loss of a dileucine-based internalization motif and disturbed lysosomal routing due to the loss of the critical machinery that is involved in leukemic transformation by several mechanisms: by causing DNA damage and an increasing mutation rate in the HSC compartment, or by inactivation of critical phosphatases such as the lipid phosphatase PTEN and protein tyrosine phosphatases that negatively control growth factor signaling.

Despite the proposed leukemogenic role of CSF3R mutations, CSF3R-D715 mice do not spontaneously develop leukemia. This might be explained by the fact that these mice had not been systematically exposed to CSF3 treatment or that their relatively short lifespan would be prohibitive to unveil the leukemogenic nature of CSF3R mutations. Alternatively, a likely hypothesis is that the transforming abilities of CSF3R mutations become overt only in the presence of the genetic defects underlying SCN (ie, mutations in ELA2, HAX1, or WAS). Because strains harboring SCN-derived mutations in Ela2 and mice deficient in Hax1 expression are available, this could be addressed by crossing the CSF3R-D715 allele into these mice. However, a complication is that the Ela2 and Hax1 mouse models do not copy the neutropenic phenotype found in patients with SCN, suggesting that in mice the consequences of these abnormalities for granulopoiesis are less severe or even lacking.

Are CSF3R mutations useful predictors for leukemic progression of SCN?

Because most patients with SCN who progress to MDS/AML have a dismal therapy outcome, it is crucial to detect signs of malignant transformation at the earliest possible stage to create the opportunity to timely consider alternative treatments, such as allogeneic stem cell transplantation (allo-SCT). Regular monitoring of CSF3R mutations has been considered to be helpful for screening the risk of leukemic transformation, but when CSF3R mutations are present in minor clones, they can easily be missed in direct sequencing protocols. Possibly, next-generation sequencing technologies allowing mutation detection in smaller subsets of cells will resolve this problem. Still, the unpredictable time intervals between the first detection of CSF3R mutations and the eventual leukemic transformation remains a dilemma that makes a decision to opt for an allo-SCT in patients with SCN who respond favorably to CSF3 treatment difficult. For that reason, the decision to perform transplantation on these patients without other additional evidence of leukemic progression (such as acquisition of monosomy 7) remains controversial, and “watchful” waiting is being considered the most acceptable option, even though the success rate of treatment at a more advanced stage of malignant transformation will significantly decline. Nonetheless, it must be taken into account that all patients with CSF3R mutations will eventually progress to AML, with time intervals varying between months, years, or even decades after the initial detection of mutant clones. A striking example of such a long latency comes from the child in whom a CSF3R mutation was first identified. CSF3 treatment of this patient started in 1990, and the CSF3R mutation was first detected in a majority of bone marrow cells in 1992. Chronologic sampling revealed that the mutant clone persisted and gave rise to refractory anemia with excess blasts in transformation (RAEBt) in 2007, rapidly followed by AML harboring trisomy 21 and a mutation in RUNX1.

Irrespective of the possible leukemogenic effects of CSF3 and CSF3R mutations in patients with SCN, the case reported here stipulates that reliable predictors of leukemic transformation allowing a timely consideration of alternative treatment are urgently needed. Systematic sequential analysis may reveal which (epi-)genetic changes that occur early on during the neutropenic phase of SCN may be linked to malignant transformation. For instance, SNP–comparative genomic hybridization (CGH) analysis in the patient with SCN in the previous paragraph suggests that copy number–neutral loss of heterozygosity (LOH), indicative of acquired uniparental disomy (UPD) in certain chromosomal regions, had already occurred in 1992 (ie, 15 years before malignant transformation; R.B. and I.P.T., unpublished results, November 2009). Because UPD is one of the hallmarks of AML, these and other genetic modifications may give new insights in the mechanisms of leukemic progression of SCN and provide valuable indicators of leukemia risk in patients with SCN, in addition to reduced CSF3 responsiveness and CSF3R mutations.

Note added in proof: In a prospective study, Ehlers et al showed a significant correlation between the expression of the CSF3R isoform IV and relapse incidence in childhood AML patients receiving CSF3 treatment.

Acknowledgments

This work was supported by grants from the Center for Translational Molecular Medicine (CTMM) and the Dutch Cancer Society for Cancer Research “KWF kankerbestrrijding.”

Authorship

Contribution: R.B. and I.P.T. wrote the paper.

Conflict-of-interest disclosure: I.P.T. is an advisor for Skyline Diagnostics BV. R.B. declares no competing financial interests.

Correspondence: Ivo P. Touw, Department of Hematology, Erasmus MC, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands; e-mail: i.touw@erasmusmc.nl.


G-CSF and its receptor in myeloid malignancy

Renée Beekman and Ivo P. Touw

Updated information and services can be found at:
http://www.bloodjournal.org/content/115/25/5131.full.html

Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml